Ipsc Derived Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Ipsc Derived Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Induced pluripotent stem cells (iPSCs) are somatic cells reprogrammed to a pluripotent state through expression of specific transcription factors. They offer unprecedented opportunities for disease modeling, drug screening, and potential cell therapy in neurodegenerative diseases.
¶ Discovery and Development
- 2006: Takahashi and Yamanaka generated first mouse iPSCs
- 2007: Human iPSCs derived from fibroblasts
- 2012: Shinya Yamanaka awarded Nobel Prize in Physiology or Medicine
- OCT4 - Pluripotency maintenance
- SOX2 - Neural rosette formation
- KLF4 - Proliferation, self-renewal
- c-MYC - Metabolic reprogramming (often omitted for safety)
- OCT4 alone - lower efficiency
- LIN28 + NANOG - alternative reprogramming
- Small molecule approaches - chemical reprogramming
- Retroviral - integration, silencing issues
- Lentiviral - better tropism
- Sendai virus - non-integrating (TempUS)
- Episomal vectors - EBNA1/oriP plasmids
- mRNA transfection - repeated delivery
- Small molecules - chemical reprogramming
- Protein transduction - direct protein delivery
- Skin fibroblasts - easy access, established
- Peripheral blood mononuclear cells
- Urine-derived cells
- Mesenchymal stem cells
- Neuronal cells - direct conversion
Embryoid Body Formation → Neural Rosette Selection → Neural Progenitor Expansion → Neuronal Maturation → Subtype Specification
- Midbrain specification - SHH, FGF8, Wnt inhibition
- Floor plate method - LMX1A, FOXA2 expression
- Floor plate-derived - authentic midbrain identity
- Retinoic acid - caudalization
- SHH - ventral patterning
- V2 interneurons - V2A specification
- Cholinergic specification - choline acetyltransferase
- Dual-SMAD inhibition - cortical identity
- Pax6 - radial glia specification
- TBR2 - intermediate progenitor
- CTIP2 - deep layer neurons
- Patient-derived neurons show Aβ42 secretion
- Elevated Aβ40/Aβ42 ratio
- Rescue with BACE inhibitors
- Hyperphosphorylated tau accumulation
- NFT-like formations
- Tau spread mechanisms
- Drug candidate testing
- Genetic modifier identification
- Mechanism of action studies
- Lewy body-like inclusions
- Progressive aggregation
- Spreading in neurons
- Complex I deficiency
- PINK1/Parkin pathway
- mtDNA mutations
- G2019S knock-in models
- Kinase hyperactivity
- Drug sensitivity testing
- Cytoplasmic mislocalization
- Aggregation
- Splicing defects
- Hexanucleotide repeat expansion
- DPR protein toxicity
- RNA foci formation
- Patient-derived motor neurons
- Drug screening platforms
- Gene editing rescue
- Huntington's Disease - mutant huntingtin
- Frontotemporal Dementia - tau, TDP-43
- Spinal Muscular Atrophy - SMN deficiency
- Friedreich's Ataxia - frataxin deficiency
- Patient-specific (autologous)
- Immune-matched
- Disease-causing mutations correctable
- Tumorigenicity risk
- Functional maturation
- Integration and connectivity
- Scalable production
| Condition |
Cell Type |
Status |
| PD |
Dopaminergic progenitors |
Phase I/II |
| AMD |
RPE cells |
Phase I/II |
| SCID |
Hematopoietic cells |
Approved |
- Personalized medicine
- Genotype-phenotype correlation
- Resistance mechanisms
- FDA-approved drug repurposing
- Novel compound testing
- Toxicity prediction
- Point mutations - base editing
- Repeat expansions - deletion/reduction
- Gene knock-in - reporters, corrections
- Patient iPSCs vs gene-corrected
- Isogenic lines for disease modeling
- Background control for screening
¶ Challenges and Limitations
- Genetic stability - chromosomal abnormalities
- Epigenetic memory - incomplete reprogramming
- Variability - line-to-line differences
- Maturation - fetal-like vs adult state
- Cost and time (6-12 months)
- Manufacturing scale-up
- Quality control
- Regulatory pathways
- Tumor formation (teratomas)
- Genetic mutations
- Immunogenicity
- Functional deficits
Ipsc Derived Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Ipsc Derived Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Takahashi K, et al. Induction of pluripotent stem cells. Cell. 2006
- Takahashi K, et al. Human iPSCs. Cell. 2007
- Kriks S, et al. Dopaminergic neurons from iPSCs. Nature. 2011
- Sances S, et al. iPSCs for neurodegenerative disease modeling. Nat Rev Neurol. 2016
- Avior Y, et al. iPSC disease modeling. Nat Biotechnol. 2016
- Quadrato G, et al. Neural differentiation from iPSCs. Nat Methods. 2016
- Finkbeiner S, et al. iPSC drug discovery for AD. Neuron. 2019